Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2025-11-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
年报信息披露重大差错责任追究制度
Regulatory Filings Classification · 95% confidence The document is titled as a "重大差错责任追究制度" which translates to "Major Error Responsibility Accountability System" related to the annual report information disclosure of Northeast Pharmaceutical Group Co., Ltd. It outlines principles, responsibilities, and procedures for accountability in case of major errors in annual report disclosures. The content is regulatory and procedural in nature, focusing on internal control and responsibility for errors in annual reports, rather than presenting actual financial data or the annual report itself. The document length is short (1737 characters), and it does not contain financial statements or substantive financial data. It is not an announcement of a report publication but a governance or regulatory compliance document related to annual report disclosures. Given the nature of the document, it fits best under Regulatory Filings (RNS) as it is a compliance and procedural document related to information disclosure, not the annual report itself or an announcement thereof.
2025-11-28 Chinese
关于变更公司注册资本、股份总数、取消监事会并修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from a company (东北制药集团股份有限公司) regarding changes to its registered capital, total shares, the abolition of the supervisory board, and amendments to the company's articles of association (公司章程). It includes extensive legal and governance-related text about the company's internal rules, board structure, shareholder rights, and procedural changes. The content focuses on corporate governance matters, including board and shareholder meeting procedures, director qualifications, and the roles of various committees. There is no indication of financial statements, audit opinions, earnings data, or investor presentations. The document is not a report of voting results but rather a formal announcement of changes to governance documents and company structure. Therefore, it fits best under the category of Governance Information (CGR). The document length and detail confirm it is the actual governance document, not just an announcement of its publication.
2025-11-28 Chinese
独立董事工作细则
Governance Information Classification · 95% confidence The document is titled '东北制药集团股份有限公司 独立董事工作细则' which translates to 'Northeast Pharmaceutical Group Co., Ltd. Independent Director Work Rules'. It details the governance structure, duties, qualifications, appointment, and working conditions of independent directors in the company. It references relevant laws, regulations, and stock exchange rules, and outlines internal governance practices related to independent directors. There are no financial statements, earnings data, or audit results. The content is focused on governance policies and internal rules for board members, specifically independent directors. Therefore, this document fits the category of Governance Information (CGR). The document length is over 6000 characters, indicating it is a full policy document rather than a brief announcement or certification.
2025-11-28 Chinese
董事和高级管理人员持有及买卖公司证券的专项管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '东北制药集团股份有限公司董事和高级管理人员持有及买卖公司证券的专项管理制度' which translates to 'Special Management System for Directors and Senior Management Personnel Holding and Trading Company Securities of Northeast Pharmaceutical Group Co., Ltd.' It outlines rules and regulations governing the holding and trading of company securities by directors and senior management, including reporting requirements, trading restrictions, disclosure obligations, and penalties for violations. It references relevant laws and regulatory frameworks such as the Company Law, Securities Law, and Shenzhen Stock Exchange rules. The document includes procedural details like application forms and confirmation letters for securities trading by insiders. This is a governance-related document focusing on internal rules and compliance for board members and senior executives regarding securities transactions. It does not contain financial statements, audit opinions, earnings data, or shareholder meeting materials. Therefore, it fits best under Governance Information (CGR). The document length (4454 characters) is sufficient for a substantive policy document, not a brief announcement or certification. Hence, the classification is CGR with high confidence.
2025-11-28 Chinese
接待和推广工作制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '东北制药集团股份有限公司接待和推广工作制度' which translates to 'Reception and Promotion Work System of Northeast Pharmaceutical Group Co., Ltd.' It outlines principles, rules, and procedures for investor relations activities such as investor meetings, roadshows, and communication with analysts and media. It references compliance with securities laws and disclosure regulations but does not contain any financial data, earnings, audit information, or report content. It is a governance-related document focusing on how the company manages investor communications and information disclosure to ensure fairness and compliance. The document is not an announcement, transcript, or report of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2025-11-28 Chinese
第十届监事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 5th meeting of the 10th Supervisory Board of Northeast Pharmaceutical Group Co., Ltd. It includes details about the meeting date, attendance, voting results on specific proposals, and references to other announcements for detailed content. The document does not contain full financial statements or detailed reports but rather announces decisions made by the supervisory board. It is not an annual report, audit report, or financial report but a regulatory announcement about board resolutions. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and it is an announcement of meeting resolutions, not the meeting materials themselves or a full report.
2025-11-28 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.